Second Sight will use the cash raised from its highly successful IPO this week to expand its centers and proceed with clinical trials, said the company's CEO Dr. Robert Greenberg. Second Sight makes the Argus II system, or so-called 'Bionic Eye', that helps restore vision for those blinded by retinitis pigmentosa. The company raised $32 million in the IPO by offering 3.5 million shares at $9 per share. There are an estimated 1.2 million people worldwide suffering from retinitis pigmentosa. The Argus II system costs around $145,000 and Dr. Greenberg said the company is already working on a next-generation version.